Navarra – May 10, 2023 – Medibiofarma S.L., a clinical-stage biotechnology company developing aportfolio of new therapies for the treatment of gastrointestinal (GI) diseases as well as othercancer and non-cancer diseases announced the first patient dosed in the Phase II clinical trial ofMBF-118...
Crohn’s & Colitis Foundation’s IBD Ventures Awards Investment to Support Development of Medibiofarma’s Novel First-In-Class PPARg Partial Agonist Oral Therapy (MBF-118) for Treatment of Crohn’s Disease Pamplona, Spain / March 3, 2023 / Medibiofarma, a...
Navarra – July 2021– Medibiofarma S.L., a clinical-stage biotechnology company developing, as part of its portfolio of projects, a new disease-modifying therapy for the treatment of neurodegeneration and cognitive decline today announced the first subject dosed in the Phase 1 clinical trial of...
Navarra – July 2021– Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of cancer and non-cancer diseases today announced the first subject dosed in the Phase Ib clinical trial of MBF-118. This compound has successfully completed...
Navarra – July 15, 2020 – Medibiofarma S.L., a clinical-stage oncology company developing new immuno-activating therapies for the treatment of cancer today announced the first subject dosed in the Phase 1 clinical trial of MBF-118, a novel covalent partial agonist of PPARg nuclear receptor. The...
Medibiofarma participated in the “Startup Spotlight” event sponsored by Eli Lilly in the 13th edition of the annual BIO-Europe Spring conference 2019 held in Vienna. Julio Castro, CSO of Medibiofarma, made the presentation of the company in a session that had more than 150 attendees over the...
Medibiofarma announces the completion of a new financing round of 2 million euros, with the financial support of its founder team and the incorporation of new partners, among them, Sodena, a public investment entity of the Government of Navarre, which has undertaken a €1-million investment...
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound will start IND enabling studies the second quarter 2019.
Compound MBF-118, a novel PPAR-γ receptor modulator for the treatment of cancer. The compound will start IND enabling studies the second quarter 2018.